During the past decade, SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 11 clinical trials were completed, i.e. on average, 55% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 9 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Takeda" with 4 trials sponsored, "Stallergenes Greer" with 3 trials sponsored, "Baxalta now part of Shire" with 2 trials sponsored and "Ferring Pharmaceuticals" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi" #1 collaborator was "Aptuit" with 2 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "Cenduit LLC" with 1 trials as a collaborator and "PHT Corporation" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi" are "Asthma" (6 trials), "Colitis, Ulcerative" (3 trials), "Chronic Inflammatory Demyelinating Polyradiculoneuropathy" (2 trials), "Crohn's Disease" (2 trials) and "Multiple Sclerosis" (2 trials). Many other conditions were trialed in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi" in a lesser frequency.

Most popular intervention types in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi" are "Drug" (24 trials), "Biological" (7 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Lebrikizumab" (3 trials), "HYQVIA" (2 trials), "MSTT1041A" (2 trials) and "Mavenclad®" (2 trials). Other intervention names were less common.

The vast majority of trials in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi" are 31 trials for "All" genders.

Currently, there are NaN active trials in "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".

SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi has several departments that took part in Clinical trials: "SPZOZ Uniwersytecki Szp. Klin. nr1 im.N.Barlickiego UM;Oddzial Kliniczny Neurologii" - 3 trials, "SPZOZ Uniwersytecki SK nr 1 im N. Barlickiego UM w Lodzi; Oddz. Klin. Gastroenter. Og. i Onk." - 2 trials